Biogen Inc (BIIB)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 43.65% | 45.63% | 50.28% | 51.41% | 50.27% | 42.76% | 43.11% | 44.37% | 48.41% | 65.53% | 73.41% | 80.77% | 86.57% | 87.65% | 87.97% | 87.47% | 86.40% | 85.97% | 85.59% | 85.72% |
| Operating profit margin | -11.98% | -13.67% | -0.84% | -4.96% | 1.76% | 13.56% | 17.03% | 22.90% | 25.87% | 17.32% | 18.94% | 29.39% | 33.84% | 46.68% | 50.93% | 51.03% | 48.98% | 47.13% | 46.90% | 42.40% |
| Pretax margin | 13.18% | 16.10% | 31.30% | 36.51% | 36.17% | 37.50% | 26.51% | 14.64% | 14.65% | 10.52% | 15.45% | 29.80% | 37.14% | 44.43% | 49.37% | 47.89% | 49.01% | 47.40% | 48.35% | 44.83% |
| Net profit margin | 11.81% | 14.63% | 26.72% | 30.99% | 29.95% | 27.64% | 19.37% | 13.40% | 14.17% | 13.93% | 16.40% | 23.89% | 29.76% | 35.63% | 40.91% | 40.76% | 40.96% | 37.91% | 37.62% | 33.79% |
Biogen Inc's profitability ratios have shown fluctuations over the past eight quarters. The gross profit margin has ranged from 74.24% to 78.35%, indicating the percentage of revenue retained after accounting for the cost of goods sold. The operating profit margin, which reflects earnings before interest and taxes, has varied between 18.62% and 28.58%. The pretax margin, a measure of profitability before accounting for taxes, has shown significant variation with a range of 13.18% to 36.50%. Lastly, the net profit margin, representing the percentage of revenue remaining after all expenses have been deducted, has fluctuated between 11.81% and 30.99%. Overall, despite some volatility, Biogen has maintained healthy profitability levels over the analyzed periods.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -4.39% | -4.85% | -0.33% | -2.04% | 0.73% | 5.65% | 7.22% | 10.49% | 11.90% | 8.08% | 9.05% | 15.53% | 18.48% | 26.70% | 28.92% | 28.18% | 25.86% | 24.41% | 25.10% | 22.15% |
| Return on assets (ROA) | 4.33% | 5.18% | 10.59% | 12.73% | 12.41% | 11.53% | 8.21% | 6.14% | 6.52% | 6.49% | 7.84% | 12.63% | 16.25% | 20.38% | 23.23% | 22.51% | 21.62% | 19.63% | 20.14% | 17.65% |
| Return on total capital | 7.15% | 12.70% | 23.13% | 28.50% | 19.67% | 32.44% | 25.97% | 16.35% | 10.09% | 13.54% | 18.98% | 37.44% | 28.66% | 60.88% | 65.03% | 56.51% | 37.40% | 49.57% | 54.03% | 46.21% |
| Return on equity (ROE) | 7.85% | 10.09% | 18.42% | 22.69% | 22.74% | 22.42% | 17.34% | 12.90% | 14.28% | 14.82% | 17.84% | 28.19% | 37.39% | 47.24% | 52.41% | 46.85% | 44.13% | 38.55% | 40.87% | 33.74% |
Biogen Inc's profitability ratios show fluctuations over the past eight quarters. Operating return on assets (Operating ROA) depicted a decreasing trend from Q1 2023 to Q4 2023, with Q1 2023 showing the highest value at 11.74% and Q4 2023 the lowest at 6.82%. Return on assets (ROA) peaked in Q1 2023 at 12.73% and gradually decreased over subsequent quarters. Return on total capital increased from Q4 2022 to Q1 2023, with Q1 2023 showing the highest value at 13.86%. Return on equity (ROE) experienced significant fluctuations, with the highest value in Q2 2023 at 18.42% and the lowest value in Q1 2022 at 12.90%.
Overall, despite some volatility in the ratios, Biogen Inc maintained relatively healthy profitability levels during the period under review. It is crucial for investors and stakeholders to monitor these ratios regularly to assess the company's efficiency in generating earnings from its assets and capital employed.